(BDSI, AZZ, GBX) CRWENewswire Stocks In Action
- uploaded: Jan 6, 2012
- Hits: 475
BioDelivery Sciences International Inc - BDSI - reported the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain. In aggregate, the agreement is worth up to $180 million to BioDelivery Sciences if all milestones are met.